Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

and will roll out throughout the U.S. in 2007. Every day, more than 4,000 people in the United States are newly diagnosed with diabetes, yet 58 percent of patients will receive no formal education about their disease. Merck is committed to improve patient care in diabetes through its significant pipeline of investigational diabetes compounds, currently marketed diabetes products (JANUVIA(TM) and JANUMET(TM)), and novel resources to support healthcare professionals and patients such as Journey for Control.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Merck forward-looking statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particula
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... SHANGHAI , Aug. 3 /PRNewswire-Asia/ -- Sangon ... company, and Bio Basic Inc. (BBI), a Toronto ... completion of,a $10 million round of funding ... scale research & development, marketing and sales of its ...
... Aug. 3 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services,Holdings Limited ... of the largest,network of radiotherapy and diagnostic imaging centers in ... for the second,quarter ended June 30, 2010 , before ... Medical,s management will hold an earnings conference call at ...
Cached Medicine Technology:Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 2Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 3Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010 2Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010 3
(Date:8/30/2014)... August 30, 2014 Continuing to meet ... is expanding with the addition of a new doctor ... who has provided leading-edge skin care in Grand Rapids ... , “As a doctor, my passion is making ... partnering with Forefront Dermatology, I’m better able to focus ...
(Date:8/30/2014)... Colorado Springs, CO (PRWEB) August 30, 2014 ... valuable, and increasingly difficult to get. Snoring and sleep apnea ... breathing stops) rob people and their bed partners of the ... Up to 45% of the population snores and 20 million ... these, only 10% have been diagnosed and treated; and of ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... result of a car accident," said one of two ... muscle strain in her shoulder and neck area. She ... invented reduced pain and pressure, assisting in comfort and ... the patent-pending PILLOW CRADLE to support the head, neck ...
(Date:8/30/2014)... Market Research Report on Global and ... and in-depth market survey on Global and Chinese ... basic information of Lab Oven including its classification, ... global and China’s top manufacturers of Lab Oven ... market share etc. , The report further analyzes ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... development company in India, Profit By Outsourcing is ... Web Development services. The company gives emphasize on putting ... the complete product to clients. Their dedicated team of ... attaining ground-breaking results. They can handle even the critical ...
Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2
... announced its approval for the use of DDT indoors, as ... pesticide, was banned// after it was found to be harmful ... Arata Kochi, director of the World Health Organization (WHO) malaria ... is indoor residual house spraying. Of the dozen pesticides WHO ...
... Studies presented at the 42nd Annual Meeting of the ... revealed that ACTOS? (pioglitazone HCl), an oral// antidiabetic medication, ... of heart attack and/or C and acute coronary syndrome ... disease (CVD) is the leading cause of premature death ...
... Researchers working closely with African American inner city ... problematic social incidents to help measure// which children ... ,"The girls preferred the cartoons over ... study leader Stephen S. Leff, Ph.D., a pediatric ...
... Hopkins has found that in addition to previously known ... of anemia in older adults, there// also exists ... ,"Our work supports the notion that mild anemia ... impairment in older adults," says Paulo Chaves, M.D., P.h.D., ...
... treatment for malaria has been developed with the help of ... in Africa. A system based on fluid// replacement for children ... in London in collaboration with the Wellcome Trust Kenya Medical ... of millions of kids, who die every year due to ...
... 1199NW has said that it supports the "Marty Smith" ... a partner when// they visit high-risk patients. Marty Smith ... of Larry Clark, a child rapist whose mother had ... his medications. ,Smith's case proves that mental ...
Cached Medicine News:Health News:ACTOS Linked to Several Cardiovascular Benefits 2Health News:ACTOS Linked to Several Cardiovascular Benefits 3Health News:ACTOS Linked to Several Cardiovascular Benefits 4Health News:Cartoons to Indicate Aggressiveness in Urban School Girls 2Health News:Cartoons to Indicate Aggressiveness in Urban School Girls 3Health News:Anemia Affects Both Body and Mind 2Health News:A Novel approach in Malaria treatment 2
... a hot air drying device for polyacrylamide and ... cellophane support for easy viewing. The assembly table ... surface for the drying frame. The dryer holds ... 115 V, 60 Hz system includes a gel ...
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
The 570-90 is capable of producing up to 500 volts or 2,500 milliamps. It is an excellent choice for running all types of electroblotting applications. Also ideal for PAGE, SDS-PAGE, and DNA or RNA s...
... techniques such as submarine electrophoresis and SDS-PAGE, ... the Series 90 Programmable Power Supplies will ... Programmable Power Supplies are available in four ... All models operate in constant voltage, current ...
Medicine Products: